Pure Diagnostic, LLC

Pure Diagnostic, LLC was paid $6.34M by Medicaid between Mar 2018 and Dec 2024, across 109 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 29% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#8 of 66

Median peer was paid$178K

This provider vs. median36×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	337	$25K
2019	8,364	$3.20M
2020	5,548	$415K
2021	38,929	$1.22M
2022	31,629	$924K
2023	16,594	$319K
2024incomplete	8,632	$233K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	29%	24,383	20,460	$1.81M
81408		12%	651	554	$760K
81406		7.2%	746	590	$458K
81298		4.3%	259	244	$274K
81317		3.9%	260	245	$247K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.7%	3,864	2,807	$232K
81201		3.6%	260	245	$231K
81292		3.6%	259	244	$230K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.6%	16,607	13,922	$229K
81321		3.6%	261	246	$227K
81295		3.2%	261	245	$201K
81405		2.7%	745	590	$169K

97 more codes

81479	Unlisted molecular pathology procedure	2.6%	704	$166K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.3%	1,514	$145K
81404		2.0%	610	$125K
81223		1.6%	110	$104K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.6%	3,498	$99K
81403		1.2%	517	$73K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	818	$42K
81242		<1%	570	$29K
81401		<1%	166	$25K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,537	$23K
87481		<1%	1,237	$20K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	809	$18K
87631		<1%	985	$17K
87496		<1%	2,090	$15K
87640		<1%	3,154	$13K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	116	$13K
81251		<1%	134	$12K
81243		<1%	110	$12K
87500		<1%	1,372	$12K
80361		<1%	1,027	$12K
87581		<1%	1,903	$12K
87498		<1%	1,834	$12K
87486		<1%	1,904	$11K
87532		<1%	1,828	$11K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,167	$11K
87653		<1%	1,190	$10K
80346		<1%	1,029	$10K
87641		<1%	1,121	$10K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	156	$10K
81209		<1%	130	$10K
81200		<1%	110	$10K
80336		<1%	1,001	$10K
81330		<1%	110	$10K
80370		<1%	1,002	$10K
81260		<1%	96	$10K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,163	$9K
81250		<1%	111	$9K
80358		<1%	1,027	$9K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	118	$9K
83992		<1%	1,028	$8K
80364		<1%	644	$8K
81249		<1%	13	$7K
80324		<1%	661	$7K
80345		<1%	1,002	$6K
80353		<1%	1,029	$5K
87529		<1%	215	$5K
87541		<1%	708	$5K
81307		<1%	27	$5K
81225		<1%	65	$3K
87563		<1%	215	$3K
81235		<1%	13	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	204	$3K
81328		<1%	151	$3K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	274	$3K
81231		<1%	65	$2K
81230		<1%	65	$2K
80363		<1%	316	$2K
81319		<1%	228	$2K
80325		<1%	347	$2K
80342		<1%	346	$2K
81240		<1%	39	$2K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	120	$2K
81241		<1%	39	$2K
87511		<1%	162	$1K
81355		<1%	39	$936.00
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	70	$712.15
81291		<1%	61	$560.00
81226		<1%	65	$560.00
81227		<1%	65	$560.00
84443	Thyroid stimulating hormone (TSH)	<1%	45	$393.98
81001		<1%	173	$316.57
80061	Lipid panel	<1%	118	$279.59
80372		<1%	1,003	$263.80
80367		<1%	1,014	$262.91
80338		<1%	1,001	$247.71
80373		<1%	1,026	$247.47
80354		<1%	1,028	$245.52
80333		<1%	1,001	$244.89
80366		<1%	1,014	$244.18
80349		<1%	1,029	$244.02
80356		<1%	1,029	$242.61
80321		<1%	20	$242.53
80365		<1%	1,028	$239.93
80359		<1%	1,029	$235.90
80360		<1%	1,016	$224.08
80348		<1%	370	$214.42
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	47	$182.26
84436		<1%	33	$119.86
84479		<1%	33	$112.81
80053	Comprehensive metabolic panel	<1%	45	$46.45
80355		<1%	988	$38.05
87150		0%	368	$0.00
81232		0%	13	$0.00
87556		0%	204	$0.00
81162		0%	207	$0.00
81435		0%	215	$0.00
80050	General health panel	0%	26	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGRAY, WILLIAM (MANAGING PARTNER)